Yingye Zheng Presents at JSM 2025
Dr. Yingye Zheng presented a new modeling framework for designing biomarker utility trials at #JSM2025. Her talk, "Raising the Bar for Launching Biomarker Utility Trial Design with Muti-stage Incidence and Mortality Modeling," explored how to link test performance to cancer mortality outcomes using real-world implementation pathways.
Zhao and Zheng Lead Session at JSM 2025
Fred Hutch biostatisticians Yingqi Zhao and Yingye Zheng are helping shape the conversation on preventive healthcare at JSM 2025. Zhao (Chair and Organizer) and Zheng (Organizer) are leading an invited session titled "Pioneering New Strategies in Preventive Healthcare: Design and Analysis Innovations."
Something is Awesome in Denmark
Dr. Yingye Zheng gave a talk, "Raising the Bar for Launching Screenign Trials — Which Criteria Should be Satisfied?" at the 2025 International Cancer Screening Network conference in Aarhus, Denmark.
Zheng at EDRN Workshop
Dr. Yingye Zheng had a poster presentation at the 14th EDRN Scientific Workshop.
Zhao Presentation
Dr. Yingqi Zhao visited the Department of Biostatistics at MD Anderson Cancer Center, and presented work on design for cancer screening trials: Addressing Real-world Challenges in Cancer Early Detection and Therapeutic Studies
A New Doctor in the House
Congratulations to Dr. Kehao Zhu on successfully earning his PhD! Well done!
Science Spotlight: Improving Randomized Cancer Screening Trials
Kehao Zhu, Yingqi Zhao and Yingye Zheng published a new paper in Biometrics offering a new approach to cancer screenign trial design. Congratulations!
Patient-Centered Outcomes Research Institute (PCORI) awards Yingqi Zhao Research Grant
The 3-year award was in response to PCORI's "Improving Methods for Conducting Patient-Centered Outcomes Research" funding announcement. The study aims to develop and improve the design and analysis of randomized screening trials (RSTs) for early cancer detection. The ultimate objective is to enable more efficient and accurate trials that assess the mortality benefits of cancer screening, while also considering the potential harms, to guide informed decision-making for screening practices.